Month: September 2026

18 September 2026

Notification no. 74/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.

For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

• APMH Invest AS – sale – 2026 09 17

Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026

CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug application (“IND”) submission to the U.S. Food and Drug Administration (the “FDA”) for the XRx-026 gout program. XORTX’s drug development plan is to seek FDA marketing approval for XRx-026 and provide patients with a new therapeutic option. The key steps the Company anticipates will be necessary to file a marketing application with the FDA include meetings with the agency, a two-part clinical study to characterize the pharmacokinetics and efficacy of the XORLO^™ formulation of oxypurinol, and manufacture of a commercial supply of XORLO^™ for the first year of marketing.

Recent drug development team activities include preparation of a new IND for submission to the FDA in the fourth quarter of 2026. The application describes the Company’s clinical development plan and its intention to file a New Drug Application (“NDA”) with the FDA following completion of the planned two-part XRX-OXY-102 clinical trial, which is being advanced based on positive and supportive prior clinical trial results and discussions with the FDA. The focus of the XRX-OXY-102 clinical trial is to characterize key information needed by the FDA in its evaluation of a future NDA filing by XORTX for marketing approval.

If the XRX-OXY-102 clinical trial is successfully completed, the Company anticipates requesting a pre-NDA meeting with the FDA and preparing an NDA submission, in parallel with pre-commercialization activities. Subject to the availability of sufficient funding and the timely completion of the XRX-OXY-102 clinical trial, XORTX is targeting an NDA submission in approximately one year. Based on prior peak net sales for febuxostat, XORTX estimates the XRx-026 program addresses an estimated US$700M market opportunity per annum.

“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” stated Allen Davidoff, Co-Chief Executive Officer of XORTX, who added, “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”

This planned submission is one part of XORTX’s broader regulatory strategy for XRx-026, and the Company looks forward to providing further updates on its international development plans.

About Hyperuricemia and Gout

In the United States, approximately 44 million individuals have uric acid levels above the normal range, with 9.2 million individuals living with gout¹. Gout is associated with severe pain, reduced quality of life², decreased physical function³, increased healthcare costs⁴, and lost economic productivity⁵. It is also strongly associated with metabolic syndrome⁵, myocardial infarction^6,7, Type 2 diabetes mellitus⁸, chronic kidney disease⁹, and premature mortality^6,10,11. Importantly, the global prevalence of gout is increasing, with cases expected to increase 70% over the next 25 years^*.

About the XRx-026 Program and XORLO™

The XRx-026 program is developing XORLO™, the Company’s proprietary formulation of oxypurinol, to treat individuals with gout. Oral xanthine oxidase inhibitors (XOIs) are the current standard of care, but limitations remain: approximately 3–5% of patients cannot tolerate allopurinol, and febuxostat, while once achieving >US$450 million in annual sales, now carries a boxed warning for cardiovascular risk. XORLO™ is designed to address this unmet need by providing an alternative therapeutic option with a differentiated safety and efficacy profile. Advancement of XRx-026 through NDA filing is a strategic priority for XORTX.

References

1. Chen-Xu M, et al. Prevalence of Gout and Hyperuricemia in the US. Arthritis Rheumatol. 2019;71(6):991–999.
2. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009;11(2):154–60.
3. Burke BT, et al. Physical Function, Hyperuricemia, and Gout in Older Adults. Arthritis Care Res. 2015;67(12):1730–8.
4. Rai SK, et al. The economic burden of gout: a systematic review. Semin Arthritis Rheum. 2015;45(1):75–80.
5. Choi HK, et al. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120(5):442–7.
6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.
7. Liu S-C, et al. Gout and Risk of Myocardial Infarction: A Systematic Review. PLoS ONE. 2015;10(7):e0134088.
8. Choi HK, et al. Gout and the risk of type 2 diabetes among men with high cardiovascular risk profile. Rheumatology. 2008;47(10):1567–70.
9. Roughley MJ, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis. Arthritis Res Ther. 2015;17(1).
10. Kuo C-F, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010;49(1):141–6.
11. Fisher MC, et al. Premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76(7):1289–94.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy, and the recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

For more information, please contact:

Allen Davidoff, Co-CEO	Mika Grasso, Co-CEO
adavidoff@xortx.com	mgrasso@xortx.com
+1 403 455 7727	+1 949 244 6011

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as well as “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “intend,” “will,” “designed to,” “positions,” and similar expressions, and include all statements that are not statements of historical fact. These forward-looking statements include, but are not limited to, statements regarding the timing and content of the Company’s planned IND submission to the FDA for the XRx-026 program; the design, initiation, conduct, and completion of the planned XRX-OXY-102 clinical trial; the timing of a pre-NDA meeting and the preparation and submission of an NDA, including the Company’s target of submitting an NDA in approximately one year; the manufacture of commercial supply of XORLO™; the Company’s estimate of the size of the U.S. market opportunity for XRx-026; the Company’s international development plans; and the advancement of the Company’s XRx-026 program, its other development programs, and its strategy.

Forward-looking statements are based on the Company’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the Company’s need for, and ability to obtain, additional capital to fund its development programs and operations; the risk that the Company’s IND submission is delayed or, once submitted, is placed on clinical hold or otherwise not permitted to proceed by the FDA; the Company’s ability to initiate, conduct, and complete the planned XRX-OXY-102 clinical trial on the timelines currently anticipated, or at all, and the risk that the results of that trial are not positive or do not support an NDA submission; the risk that the FDA does not agree with the Company’s proposed clinical development plan or regulatory pathway, or requires additional studies or data; the Company’s reliance on third-party contract research organizations and contract manufacturers; the risk that the Company’s estimates of market size, which are based on third-party data and the historical sales of other products, prove to be inaccurate; competition from existing and future therapies for gout; the Company’s ability to advance, and obtain regulatory approval for, the XRx-026 program and its other product candidates on the timelines currently anticipated, or at all; the evolving regulatory environment applicable to the Company’s business in the United States and Canada; and the Company’s ability to attract and retain qualified personnel.

For a more detailed discussion of these and other risks and uncertainties, investors should review the disclosures contained under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and in the Company’s subsequent Reports of Foreign Private Issuer on Form 6-K, each as filed with or furnished to the SEC and available at www.sec.gov, as well as in the Company’s continuous disclosure documents filed with the Canadian securities regulatory authorities and available at www.sedarplus.ca.

The forward-looking statements in this press release speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.

__________________________
* https://pubmed.ncbi.nlm.nih.gov/38996590/

ENCINO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, will hold a conference call on Monday, September 28, 2026, at 9:00 am Eastern Time (6:00 am Pacific Time) to discuss its financial results for the fourth quarter and full fiscal year ended June 30, 2026. A question-and-answer session will follow management’s prepared remarks.

Date: Monday, September 28, 2026
Time: 9:00 am Eastern Time (6:00 am Pacific Time)
Participant listening: 1-877-407-0789 or 1-201-689-8562

The conference call will also be broadcast live and available for replay here (the link will be made active 15 minutes prior to scheduled start time), along with additional replay access being provided through the company information section of NETSOL’s website.

Telephone replays will be made available approximately 3 hours after conference end time.

Telephone replay
Replay dial-In: 1-844-512-2921 or 1-412-317-6671
Replay expiration: Monday, October 12, 2026 at 11:59 PM ET
Access ID: 13762610

About NETSOL Technologies 
NETSOL Technologies delivers state-of-the-art solutions for the asset finance and leasing industry, serving automotive and equipment OEMs, auto captives and financial institutions across over 30 countries. Since its inception in 1997, NETSOL has been at the cutting edge of technology, pioneering innovations with its asset finance solutions, and today leverages advanced AI and cloud services to meet the complex needs of the global market. Renowned for its deep industry expertise, customer-centric approach and commitment to excellence, NETSOL fosters strong partnerships with its clients, ensuring their success in an ever-evolving landscape. With a rich history of innovation, ethical business practices and a focus on sustainability, NETSOL is dedicated to empowering businesses worldwide, securing its position as the trusted partner for leading firms around the globe.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s products and services, expectations for future operations, and other statements that are not historical facts. These forward-looking statements may be identified by terminology such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” and similar expressions. These statements are not guarantees of future performance and are subject to a number of risks, uncertainties, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the timing of customer go-lives and contract renewals, the rate of adoption of AI-enabled product capabilities, foreign currency volatility, and other factors discussed in NETSOL’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NETSOL undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:
Investor Relations
(818) 222-9195
investors@netsoltech.com

LOS ANGELES, Sept. 18, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a defense technology and artificial intelligence company, today announced that it will effect a 1-for-20 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”).

The Reverse Stock Split will become effective at 12:01 a.m., Eastern Time, on September 22, 2026. The Company’s common stock will continue to trade on The Nasdaq Global Market under the symbol “VWAV” and is expected to begin trading on a split-adjusted basis when the market opens on September 22, 2026. The common stock will be assigned a new CUSIP number, 927950204.

At the Company’s 2026 Annual Meeting of Stockholders held on September 1, 2026, the stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of common stock at a ratio of not more than 1-for-250, with the exact ratio and the timing thereof to be determined by the Board of Directors in its sole discretion. On September 3, 2026, the Board of Directors set the ratio at 1-for-20 and approved the filing of a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which the Company filed on September 16, 2026.

The Reverse Stock Split is primarily intended to increase the per share trading price of the Company’s common stock in order to maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1).

As a result of the Reverse Stock Split, every twenty (20) shares of the Company’s issued and outstanding common stock, and shares held in treasury, will automatically be combined into one (1) share of common stock. The Reverse Stock Split will reduce the number of issued and outstanding shares of common stock from approximately 47.5 million shares to approximately 2.4 million shares, subject to adjustment for the rounding up of fractional shares described below. The Reverse Stock Split will not change the par value of the common stock, which will remain $0.01 per share, and will not change the number of authorized shares of the Company’s capital stock, which will remain 160,000,000 shares, consisting of 150,000,000 shares of common stock and 10,000,000 shares of preferred stock. Accordingly, the number of authorized but unissued shares of common stock available for future issuance will increase substantially relative to the number of shares outstanding, and future issuances of those shares could be dilutive to existing stockholders.

No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional share that would otherwise result from the Reverse Stock Split will be rounded up to the next whole share. For this purpose, all shares of common stock held of record by a stockholder immediately prior to the effective time will be aggregated. No stockholder will receive a cash payment in lieu of a fractional share, and no stockholder will be cashed out of the Company as a result of the Reverse Stock Split.

Proportionate adjustments will be made to the number of shares of common stock issuable upon the exercise, conversion or vesting of the Company’s outstanding warrants, pre-funded warrants, stock options, restricted stock units and convertible notes, and to the applicable exercise, conversion or purchase prices thereof, as well as to the number of shares reserved for issuance under the Company’s equity incentive plans, in each case in accordance with the terms of the applicable instrument or plan.

Stockholders holding shares in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the Reverse Stock Split; their positions will be adjusted automatically to reflect the Reverse Stock Split. Beneficial holders with questions regarding the processing of the Reverse Stock Split should contact their bank, broker or other nominee. Registered stockholders holding shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust Company, will receive information from the transfer agent regarding their holdings following the effective time. Additional information regarding the Reverse Stock Split is contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 23, 2026, and in the Current Report on Form 8-K to be filed by the Company in connection with the Reverse Stock Split.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the effective time of the Reverse Stock Split, the expected commencement of split-adjusted trading, the anticipated effect of the Reverse Stock Split on the per share trading price of the common stock, the Company’s expectations regarding continued listing on The Nasdaq Global Market, and the anticipated post-split share counts. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to: the risk that the Reverse Stock Split does not result in a sustained increase in the per share trading price of the common stock, or that the price declines following the Reverse Stock Split; the risk that the Reverse Stock Split does not enable the Company to maintain compliance with the Nasdaq minimum bid price requirement or any other continued listing standard, and the risk of delisting; the risk that the Reverse Stock Split reduces the liquidity or marketability of the common stock, or increases the number of stockholders holding odd lots; the substantial increase in authorized but unissued shares of common stock available for future issuance and the potential dilution to existing stockholders resulting from future issuances, including under the Company’s at-the-market offering arrangements, outstanding convertible notes, warrants and pre-funded warrants, and equity incentive plans; the Company’s need for additional capital and the terms on which it may be available; the effect of the Reverse Stock Split on the conversion, exercise and floor price provisions of the Company’s outstanding securities; the risk of delay in the effectiveness or processing of the Reverse Stock Split by the Secretary of State of the State of Delaware, Nasdaq, the Company’s transfer agent or The Depository Trust Company; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact for Investors: investors@vwav.inc

Jill Van, EVP & Controller, to succeed Cary Dickson following his planned retirement

KPMG appointed as Auditor

COSTA MESA, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — Gold.com, Inc. (NYSE: GOLD), (“Gold.com” or the “Company”), a fully integrated alternative assets platform that offers an extensive range of precious metals, numismatic coins, and collectibles to consumers, collectors, and institutional clients worldwide, today announced that its Board of Directors has appointed Jill Van as Chief Financial Officer, effective September 18, 2026. She succeeds Cary Dickson, who has informed the Company of his decision to retire on the same date. Mr. Dickson will serve as a Consultant to the Company for the 12 month period immediately following his retirement. The Company also announced that the Audit Committee of the Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027, succeeding Grant Thornton LLP.

Appointment of Jill Van as Chief Financial Officer

Ms. Van currently serves as Executive Vice President and Controller and will transition to the Chief Financial Officer role on September 18, 2026 , succeeding Cary Dickson following his planned retirement. She joined the Company in June 2025 and has more than 25 years of accounting, audit, and financial leadership experience. Ms. Van is a Certified Public Accountant and spent more than two decades in public accounting, including Audit Partner roles at RSM US LLP and Grant Thornton LLP, where she led SEC reporting engagements, audits, and complex transactions across diverse range of clients. She also served as Interim CFO at Hardesty LLC and was CFO at Shew Enterprises.

“With Cary transitioning into retirement, Jill is exactly the right person to step into the CFO role,” said Greg Roberts, Chief Executive Officer of Gold.com. “She has already been a driving force behind our finance organization, and her decades of experience give her the technical depth to oversee our financial reporting and controls as a public company. On behalf of the Board and the entire Gold.com team, I also want to thank Cary for his many contributions over more than a decade of service, and we wish him well in his retirement.”

“It has been an honor to serve as Gold.com’s Chief Financial Officer on two separate occasions over the past 11 years, and to help lead the Company through its significant transformation and global expansion,” said Cary Dickson. “I’ve worked closely with Jill and know firsthand the commitment and judgment she brings to the finance organization. I’m confident she is ideally suited to be Gold.com’s next CFO.”

“I am grateful to Cary for his mentorship and to the Board for this opportunity,” said Jill Van. “Having spent the past year immersed in our financial reporting and operations as Controller, I am looking forward to building on that foundation of strong financial discipline to support our strategic priorities around growth, capital efficiency and operational excellence.”

Appointment of KPMG LLP as Independent Auditor

As Gold.com’s business continues to evolve on a global scale, the Audit Committee of the Board of Directors conducted a review process to determine the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The Audit Committee has approved the appointment of KPMG to serve as Gold.com’s independent registered public accounting firm, effective September 14, 2026. KPMG succeeds Grant Thornton LLP, whom the Company thanks for its service. Additional information is available in the Current Report on Form 8-K to be filed with the Securities and Exchange Commission.

About Gold.com, Inc.

Gold.com builds on gold’s storied history and heritage to define the future of alternative asset management. Founded in 1965, Gold.com offers comprehensive solutions for all aspects of the precious metals (gold, silver, platinum, and palladium) and collectibles (including rare coins and currency) value chains. Its vertically integrated platform combines market expertise with state-of-the-art logistics, financing, and minting capabilities to serve customers, collectors, and institutional clients globally.

Gold.com’s direct-to-consumer marketplace, anchored by flagship brands JMBullion.com, Stack’s Bowers Galleries, GovMint.com, Monex Precious Metals, and Goldline, has served millions of customers. The Company’s trading and wholesale sales platform, which operates as A-Mark Precious Metals, maintains distribution and finance focused relationships with a network of sovereign and private mints and has been an “authorized purchaser” of the United States Mint since 1986. This platform is supported by the Company’s minting and refining operations which include Sunshine Minting and Silver Towne Mint, whose facilities can collectively produce in excess of three million ounces of finished precious metals products per week. Gold.com’s Collateral Finance Corporation secured lending subsidiary, CFCGoldLoans.com, extends bullion, numismatic, and graded sports card loans, while A-Mark Global Logistics supports the Company’s operations with airport-adjacent distribution centers and IRA-approved storage depositories.

Gold.com is headquartered in Costa Mesa, California, and operates across the United States, Canada, the United Kingdom, Europe, Hong Kong, and Singapore. Learn more at www.gold.com.

Gold.com periodically provides information for investors on its corporate website, www.gold.com and its investor relations website, ir.gold.com. This includes press releases and other information about financial performance, reports filed or furnished with the SEC, information on corporate governance, and investor presentations.

Important Cautions Regarding Forward-Looking Statements

Statements in this press release that relate to future plans, objectives, expectations, performance, events and the like are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934. These include statements regarding expectations with respect to growth, increasing market share and the delivery of long-term value. Future events, risks and uncertainties, individually or in the aggregate, could cause actual results or circumstances to differ materially from those expressed or implied in these statements. Factors that could cause actual results to differ include the following: The failure to execute the Company’s growth strategy, including the inability to identify suitable or available acquisition or investment opportunities; greater than anticipated costs incurred to execute this strategy; our inability to execute on our cost containment and expense reduction programs; government regulations that might impede growth, particularly in Asia, including with respect to tariff policy; the inability to successfully integrate our recently acquired businesses; changes in the current international political climate, which historically has favorably contributed to demand and volatility in the precious metals markets but also has posed certain risks and uncertainties for the Company; increased competition for the Company’s higher margin services, which could depress pricing; the failure of the Company’s business model to respond to changes in the market environment as anticipated; changes in consumer demand and preferences for precious metal products generally; potential negative effects that inflationary pressure may have on our business; the failure of our investee companies to maintain, or address the preferences of, their customer bases; general risks of doing business in the commodity markets; and the strategic, business, economic, financial, political and governmental risks and other Risk Factors described in in the Company’s public filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

Company Contact:
Steve Reiner, Executive Vice President, Capital Markets & Investor Relations
Gold.com, Inc.
1-310-587-1410
sreiner@gold.com

Investor Relations Contact:
Reed Anderson, ICR
646-277-1260
reed.anderson@icrinc.com
GOLD@icrinc.com

ROAD TOWN, British Virgin Islands, Sept. 18, 2026 (GLOBE NEWSWIRE) — Aura Minerals Inc. (“Aura Minerals” or the “Company” or the “Borrower”) (NASDAQ: AUGO | B3: AURA33) announced today that it has entered into a syndicated loan facility (the “Loan”), in the aggregate principal amount of US$ 200,000,000.00 (two hundred million dollars), as borrower at the holding company level.

Citigroup Global Markets Inc. (“Citi”) and Itaú BBA Assessoria Financeira S.A., acted as joint lead arrangers and bookrunners for the Loan.

The Loan will bear interest at a rate of SOFR + 2.70% per year with two years grace period and maturity of 5 years. The Company intends to use the net proceeds to finance the Borrower’s (or any of its subsidiaries’) payments to suppliers and/or to finance the prepayment of its costs of producing and selling its goods.

Rodrigo Barbosa, CEO and President, commented: “We are pleased to announce this USD 200 million syndicated loan facility, a further step in strengthening Aura’s capital structure and extending our financial flexibility as we keep increasing our production towards our target of producing over 600k GEO per year in the medium term, including the ongoing construction of Era Dorada and expansion of production capacity at Almas and the expected expansion of Borborema. Securing this Loan at a SOFR + 2.70% reflects our operational momentum, robust cash generation and disciplined growth strategy. At Aura, our approach to capital allocation remains balanced and consistent — combining prudent liability management with continued investment in our growth pipeline, while maintaining the financial discipline that has defined our track record. This transaction further diversifies our funding sources and supports the current phase of value creation for our shareholders under the Aura 360 culture.”

About Aura 360° Mining

Aura is focused on mining in complete terms – thinking holistically about how its business impacts and benefits every one of our stakeholders: our company, our shareholders, our employees, and the countries and communities we serve. We call this 360° Mining.

Aura is a company focused on the development and operation of gold and base metal projects in the Americas. The Company’s six operating assets include Minosa gold mine in Honduras; Almas, Apoena, Borborema and MSG gold mines in Brazil; and Aranzazu, a copper, gold, and silver mine in Mexico. Additionally, the Company owns Era Dorada, a gold project in Guatemala; Tolda Fria, a gold project in Colombia; and two projects in Brazil: Matupá, which is under development; and the Carajás copper project in the Carajás region, in the exploration phase.

CONTACT: For further information, please visit Aura’s website at www.auraminerals.com or contact:

Investor Relations

ri@auraminerals.com